The gap between the first and the increased dose of Pfizer (NYSE: PFE) and BioNTechsay (NASDAQ: BNTX) the coronavirus vaccine has been widely used in the UK – and Pfizer is not happy about it.
The UK Joint Vaccination and Vaccination Committee, an advisory body advising government agencies, has new dosing guidelines for both Pfizer / BioNTech’s BNT162b2 and the newly approved AZD1222 of AstraZeneca and the University of Oxford. The new guidelines stipulate that the two required shots of both vaccines can be administered up to three months apart.
The main purpose of the new recommendation seems to be to get as many people vaccinated as possible with the initial survey. Research suggests that partial protection against the coronavirus may begin as early as 12 days after the first sample.
Image Source: Getty Images.
According to the Financial Times“Pfizer said,”[Our] study … was designed to evaluate the safety and efficacy of the vaccine according to a two-dose schedule, separated by 21 days … The safety and efficacy of the vaccine were not evaluated on different dosing schedules, as the majority of participants in the trial the second dose within the window specified in the study design. ”
It is also said that there are no data indicating that the initial dose of the vaccine is effective after those 21 days.
The amended recommendation caused some unrest in the country FT wrote. Doctors were forced to revise the scheduling for patients, with the goal of returning a few days after their initial shot for an amplifier. The newspaper reported dr. Helen Salisbury, a general practitioner in Oxford, was quoted as saying that the situation was “a mess”.
Neither Pfizer nor BioNTech outperformed the S&P 500 index on Thursday. The former company’s share increased by only 0.2% on the day, while the latter’s shares fell by 2.9%.